The rising cost of living compounds the difficulties faced by low-income families with children, creating an urgent need for support, says Heidi Herranen, Coordinator of Save the Children Finland’s Fuel…
Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s…
A new oral vaccine for cholera has received prequalification by the World Health Organization (WHO) on 12 April. The inactivated oral vaccine Euvichol-S has a similar efficacy to existing vaccines…
Today marked a significant milestone in healthcare as the World Health Organization (WHO) unveiled the Patient Safety Rights Charter during the Global Ministerial Summit on Patient Safety. This groundbreaking Charter,…
In collaboration with public health agencies and experts worldwide, the World Health Organization (WHO) has released a comprehensive report introducing updated terminology for pathogens transmitted through the air. The report,…
The advent of new drugs targeting diabetes, obesity, and cardiovascular diseases has sparked a surge in the demand for polypeptide manufacturing. This surge, in turn, has propelled an industrial intensification…
Today, the joint effort of the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO) culminated in the publication of a comprehensive report detailing the outcomes…
UCB’s FINTEPLA®▼ (fenfluramine) oral solution has received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating seizures linked with Lennox-Gastaut syndrome (LGS) as an additional therapy…
Merck’s Curiosity Cube Hits the Road: Inspiring 45,000 Students Across 14 Countries Merck, a global leader in science and technology, has launched its 2024 Curiosity Cube tour from Darmstadt, Germany,…
Australia’s Latest Biotech Incubator, Jumar Bioincubator, Unveils First Cohort of Innovative Ventures Melbourne, Australia – Jumar Bioincubator, the newest addition to Australia’s biotech landscape, has officially opened its doors, showcasing…
Sanofi’s frexalimab, a CD40L antibody, has displayed enduring effectiveness and favorable tolerability over almost a year in individuals with relapsing multiple sclerosis (MS). These findings will be unveiled today at…
Novartis has unveiled findings from the ALITHIOS open-label extension study, spotlighting the enduring effectiveness of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing…